In Canada, provincial and territorial laws address circumstances in which a substitute decision-maker may be appointed for an adult deemed legally incapable of making decisions in one or more areas of life. We searched for provincial and territorial laws that explicitly address substitute decision-making about research participation, and found significant differences among Canadian jurisdictions. In some provinces and territories there is no direct statutory guidance on the issue. Differences among jurisdictions that address substitute decision-making about research in legislation include whether judicial intervention is required to authorize the substitute decision-maker, whether any advance directive in place must explicitly authorize the decision about research in order for a proxy to consent, and how risk and benefit thresholds beyond which substitute consent to research is prohibited are articulated. It is imperative that government, researchers, and the Canadian public revisit the principles underpinning substitute decision-making about research in light of national and international norms, in order to lend clarity and consistency to this area of law and research practice.

Download full-text PDF

Source
http://dx.doi.org/10.1353/cja.2005.0074DOI Listing

Publication Analysis

Top Keywords

provincial territorial
12
substitute decision-making
12
substitute consent
8
territorial laws
8
substitute decision-maker
8
address substitute
8
substitute
7
comparison provincial
4
territorial legislation
4
legislation governing
4

Similar Publications

Background: From 2002 to 2023, palivizumab was the only intervention to reduce RSV-associated hospitalizations in high-risk infants in Canada, but advances in RSV prevention are drastically changing this landscape. Eligibility criteria for this monoclonal antibody for preterm infants varied over time across each of 10 Canadian provinces and 3 territories. The national professional pediatric association (Canadian Paediatric Society) revised its eligibility recommendations in 2015, removing access for preterm infants 30 to 32 weeks gestation (WG).

View Article and Find Full Text PDF

Global, regional, and national incidence and mortality for enteric infections from 1990 to 2019.

BMC Public Health

January 2025

Institute of Occupational Health and Environmental Health, School of Public Health, Lanzhou University, Lanzhou, Gansu, 730000, China.

Background: Enteric infections are among the most common infectious diseases. The aim of this article was to track the global trends in morbidity and mortality from enteric infections in 204 countries or territories from 1990 to 2019.

Methods: Data were obtained from the Global Burden of Disease 2019 study.

View Article and Find Full Text PDF

Background: This study aims to delineate the global, regional, and national burden of malignant neoplasms of bone and articular cartilage (MNBAC) among individuals aged 65 years and older from 1990 to 2021, stratified by age, sex, and sociodemographic index (SDI).

Methods: We harnessed data from the Global Burden of Disease Study 2021 to evaluate the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) associated with MNBAC among individuals aged 65 years and older across 204 countries and territories between 1990 and 2021. The socio-demographic Index (SDI) served as a metric to examine the influence of socioeconomic development on the burden of MNBAC.

View Article and Find Full Text PDF

Background: Heart failure (HF) presents a significant global health challenge due to its rising prevalence and impact on disability.

Aims: This study aims to comprehensively analyze the global burden of HF and its underlying causes.

Methods: Using data from the Global Burden of Disease Study 2021, we analyzed the prevalence and Years Lived with Disability (YLD) of HF, examining its implications across diverse demographics and geographic regions.

View Article and Find Full Text PDF

Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) are prevalent in over 80 countries or territories worldwide, causing hundreds of thousands of cases annually. But currently there is a lack of specific antiviral agents and effective vaccines.

Methods: In the present study, to identify human neutralizing monoclonal antibody (mAb) against JEV or/and ZIKV, we isolated ZIKV-E protein-binding B cells from the peripheral venous blood of a healthy volunteer who had received the JEV live-attenuated vaccine and performed 10× Genomics transcriptome sequencing and BCR sequencing analysis, we then obtained the V region amino acid sequences of a novel mAb LZY3412.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!